CA2893200C - C20'-urea derivatives of vinca alkaloids - Google Patents

C20'-urea derivatives of vinca alkaloids Download PDF

Info

Publication number
CA2893200C
CA2893200C CA2893200A CA2893200A CA2893200C CA 2893200 C CA2893200 C CA 2893200C CA 2893200 A CA2893200 A CA 2893200A CA 2893200 A CA2893200 A CA 2893200A CA 2893200 C CA2893200 C CA 2893200C
Authority
CA
Canada
Prior art keywords
ring
hydrocarbyl
group
vinca alkaloid
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2893200A
Other languages
English (en)
French (fr)
Other versions
CA2893200A1 (en
Inventor
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA2893200A1 publication Critical patent/CA2893200A1/en
Application granted granted Critical
Publication of CA2893200C publication Critical patent/CA2893200C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2893200A 2012-12-03 2013-08-23 C20'-urea derivatives of vinca alkaloids Active CA2893200C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732687P 2012-12-03 2012-12-03
US61/732,687 2012-12-03
PCT/US2013/056459 WO2014088657A1 (en) 2012-12-03 2013-08-23 C20'-urea derivatives of vinca alkaloids

Publications (2)

Publication Number Publication Date
CA2893200A1 CA2893200A1 (en) 2014-06-12
CA2893200C true CA2893200C (en) 2018-04-24

Family

ID=50883853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893200A Active CA2893200C (en) 2012-12-03 2013-08-23 C20'-urea derivatives of vinca alkaloids

Country Status (6)

Country Link
US (1) US9611271B2 (https=)
EP (1) EP2925760B1 (https=)
JP (1) JP6326697B2 (https=)
AU (1) AU2013356664B2 (https=)
CA (1) CA2893200C (https=)
WO (1) WO2014088657A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464289B1 (en) * 2016-05-31 2021-04-21 The Scripps Research Institute Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tubulin dimer-dimer interface
CA2993378C (en) * 2017-09-15 2021-10-05 The Scripps Research Institute Vinblastine 20' amides: synthetic analogs that maintain or improve potency and simultaneously overcome pgp-derived efflux and resistance
CN108675992B (zh) * 2018-06-20 2020-11-27 浙江药苑生物科技有限公司 一种作用于微管蛋白的抗肿瘤药物
CN108864053B (zh) * 2018-06-20 2020-12-01 浙江药苑生物科技有限公司 一种微管蛋白抑制剂及其在抗肿瘤药物中的应用
KR20260040225A (ko) * 2023-06-13 2026-03-24 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 플라스모디움 팔시파룸 혈액 단계 억제제
WO2026007326A1 (zh) * 2024-07-01 2026-01-08 四川大学 长春碱衍生物的制备及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322351A (en) * 1980-08-25 1982-03-30 Eli Lilly And Company Antineoplastic 4'-formylamino and 4'-acetylamino VLB, and derivatives thereof
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
US8039453B2 (en) * 2006-09-12 2011-10-18 Albany Molecular Research, Inc. Vinca derivatives
WO2011103007A2 (en) * 2010-02-22 2011-08-25 The Scripps Research Institute 10'-fluorinated vinca alkaloids provide enhanced biological activity against mdr cancer cells

Also Published As

Publication number Publication date
EP2925760A4 (en) 2015-10-21
EP2925760A1 (en) 2015-10-07
US20150291610A1 (en) 2015-10-15
WO2014088657A1 (en) 2014-06-12
JP2016507483A (ja) 2016-03-10
AU2013356664B2 (en) 2018-01-18
JP6326697B2 (ja) 2018-05-23
AU2013356664A1 (en) 2015-06-18
CA2893200A1 (en) 2014-06-12
EP2925760B1 (en) 2018-02-21
US9611271B2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
EP3464289B1 (en) Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tubulin dimer-dimer interface
CA2893200C (en) C20'-urea derivatives of vinca alkaloids
EP3283462B1 (en) Fused-tricyclic inhibitors of kras and methods of use thereof
EP4361142A1 (en) Compound as kif18a inhibitor
EP3733663B1 (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
JP2000501408A (ja) 特に抗増殖性を有する新規プリン誘導体およびそれらの生物学的用途
US8940754B2 (en) 10′-fluorinated Vinca alkaloids provide enhanced biological activity against MDR cancer cells
WO2021223736A1 (en) Compounds as bcl-2 inhibitors
WO2021074251A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer
WO2020063751A1 (en) Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
WO2022061155A1 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
EP4089092B1 (en) Polycyclic compound acting as kinase inhibitor
El-Sheref et al. Synthesis of novel amidines via one-pot three component reactions: Selective topoisomerase I inhibitors with antiproliferative properties
CA2993378C (en) Vinblastine 20' amides: synthetic analogs that maintain or improve potency and simultaneously overcome pgp-derived efflux and resistance
WO2023250513A1 (en) 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
HK40040029B (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
HK40040029A (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260408